Press release 2014-09-04 C-RAD has received an order for a total of four systems and a long-term service contract from the
Clinic for Radiation Therapy and Radio Oncologyin LÜneberg, Germany. The order comprises two Catalyst systems, a Sentinel 4DCT system and a Cyrpa Laser system for virtual simulation. The Clinic for Radiation Therapy and Radio Oncologyis specialized in the treatment of abdominal cancer as well as head & neck and thorax tumors. This includes breast and lung cancer. The position of these tumors is dependent on respiratory motion, therefore an increasing number of customers use 4D techniques to offer an optimized treatment. The Catalyst system is based on a new generation of hardware and software platforms for high-performance optical surface scanning and augmented reality through re-projection. Advanced and highly optimized algorithms for non-rigid registration and deformable models enable real-time assessment of patient positioning errors before and during treatment delivery. The system calculates isocenter adjustments and with interfaces to major vendors, a completely integrated workflow is ensured. As part of the cooperation between C-RAD and Cyrpa, a unique product combination for 4D imaging and virtual simulation has been developed. All systems for virtual simulation and 4D imaging sold by C-RAD and Cyrpa will be delivered with the C-RAD software platform. Installation for this project will start in the beginning of the fourth quarter 2014. "With our current product portfolio, we offer an attractive package to our customers. The advantages of an integrated solution for virtual simulation and 4D imaging are convincing. This project is evidence of the strong interest in our new service offerings that we have developed during the year." says Tim Thurn, CEO of C-RAD AB About C-RAD C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging ABand C-RAD Innovation AB. All companies are located in Uppsala. Numbers of employees are currently 27 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the companyís first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varianand the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporatedin the US, C-RAD GmbHin Germanyand C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010listed at Nasdaq Omx First North Premier. Erik Penser Bankaktiebolagis appointed as C-RADís Certified Adviser. For more information on C-RAD, please visit www.c-rad.com. For further information: Tim Thurn, CEO C-RAD AB, Phone +46-18-666947, E-mail email@example.com The above information is price sensitive and must therefore be disclosed under the Securities Market Act (2077:528). Copyright © 2014 OMX AB (publ).